Additive and Supra-Additive Effects

An additive effect is the benchmark of no interaction: the combined effect of two drugs is exactly what their individual contributions predict. A supra-additive effect exceeds that prediction. Because 'additive' is a prediction and not a single observable number, defining additivity requires a reference model, and the two classical models, Loewe dose-additivity and Bliss independence, can give different baselines.

Definition

An additive effect is a combined drug effect equal to that predicted by a no-interaction reference model from the drugs' individual effects; a supra-additive effect is one that exceeds this prediction, indicating synergy under the chosen model.

Scope

This topic covers the meaning of additivity and supra-additivity, the two principal reference models that define the additive baseline (Loewe additivity and Bliss independence), and how observed combinations are compared against that baseline using the isobologram, the interaction index, and the combination index. It is a quantitative-pharmacology reference and does not address specific therapeutic combinations or doses.

Core questions

• What does 'additive' mean, and why does it require a reference model?
• How do Loewe dose-additivity and Bliss independence differ?
• When is dose-additivity the appropriate baseline?
• How is a supra-additive (synergistic) departure detected and measured?
• What does an interaction index value indicate?

Key concepts

• Additivity as a no-interaction baseline
• Loewe dose-additivity
• Bliss independence
• Line of additivity
• Interaction index
• Supra-additivity (synergy) versus infra-additivity
• Reference-model dependence

Key theories

Loewe dose-additivity

Treats two drugs as dilutions of one another sharing a common mechanism; additivity is the line connecting the equieffective doses of each drug alone, and the interaction index measures deviation from it.

Bliss independence

Treats drugs as acting independently on the same outcome, so the expected combined fractional effect is computed by probabilistic independence; departures define synergy or antagonism under that assumption.

Mechanisms

Additivity is a prediction generated by a reference model, then compared with the observed combined effect. Under Loewe dose-additivity, two drugs are assumed to act as though they were the same agent at different potencies; the combination is additive if achieving a given effect uses doses lying exactly on the isobole connecting each drug's equieffective dose. Tallarida's interaction index expresses how far the observed combination sits from that line, with values below one indicating supra-additivity. Under Bliss independence, the drugs are assumed to act independently, and the expected combined effect follows from multiplying their non-effect fractions. The model chosen matters because the same data can be additive under one model and supra-additive under the other; Loewe additivity is generally the appropriate baseline when the drugs share a mechanism.

Clinical relevance

Distinguishing a merely additive combination from a genuinely supra-additive one underlies how combination evidence is read, including evidence about reinforced therapeutic or adverse effects. This entry is a conceptual reference for that distinction and does not provide combination, dosing, or treatment recommendations.

Evidence & guidelines

The supporting evidence is methodological: Tallarida's interaction-index and isobole work (2002, 2011, 2012) and Chou's combination-index framework (2006) define how additivity is specified and how supra-additive departures are quantified. These are analytic reference methods, not clinical guidelines.

History

Loewe's isobolographic concept of dose-additivity and Bliss's independence criterion, both formulated in the first half of the twentieth century, provided the two enduring definitions of an additive baseline. Tallarida later gave the interaction index a statistical footing, and Chou and Talalay's median-effect approach embedded additivity within a combination-index framework spanning the dose-response curve.

Debates

Which reference model defines 'additive'?

Loewe dose-additivity and Bliss independence rest on different assumptions (shared versus independent mechanism) and can classify the same combination differently; there is no single universally correct baseline, so model choice must be justified.

Key figures

• Sigmund Loewe
• C. I. Bliss
• Ronald J. Tallarida
• Ting-Chao Chou

Seminal works

• chou-2006
• tallarida-2002
• tallarida-2012

Frequently asked questions

Is 'additive' the same as 'no interaction'?

Yes, in the technical sense: an additive effect is the effect predicted when the drugs do not interact at the effect site. Whether a combination counts as additive depends on which no-interaction reference model is applied.

Why can two analysts disagree about whether a combination is synergistic?

Because synergy is defined relative to an additive baseline, and the Loewe and Bliss models can yield different baselines. A combination that is supra-additive under one model may be additive under the other.